What cancer researchers, clinicians and patients say about ‘game-changing’ GLP-1s
Researchers are investigating whether GLP-1 receptor agonist drugs have cancer prevention potential, with data showing a reduced risk of colorectal cancer in GLP-1 users. One in eight adults in the U.S. is currently taking a GLP-1 drug, but concerns exist about muscle loss and malnutrition associated with rapid weight loss.
GLP-1 receptor agonist drugs are being studied for their potential in cancer prevention. Data presented at the 2026 ASCO Gastrointestinal Cancers Symposium showed a reduced risk of colorectal cancer in GLP-1 users. One in five adults in the U.S. has taken a GLP-1 drug, and 12% are currently using it. However, concerns exist about muscle loss associated with rapid weight loss. Researchers stress that exercise, not just protein intake, is necessary to build muscle. Some experts recommend that patients using GLP-1 drugs be referred to registered dietitians to create healthy eating patterns and avoid malnutrition.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.